Published in Psychiatry and Clinical Neurosciences
The First diagnostic plasma metabolite biomarker for Major Depression Disorder (MDD) has been published in Psychiatry and Clinical Neurosciences.
HMT and Toyobo and MDD
HMT and Toyobo have established production of Ethanolaminephosphate phospho-lyase for clinical assay relating Major Depression Disorder (MDD).
HMT Begins New Contract with NIH/NIA
HMT begins a new contract with NIA, NIH to study brain metabolomic profiles in Alzheimer’s disease.
HMT signed a Licensing Agreement with Sysmex Corporation for Biomarker Kit for Depressive Disorder
HMT has researched and developed a blood
biomarker for Depressive Disorder in cooperation with
National Center of Neurology and Psychiatry and GYOKIKAI Medical Corporation.
HMT joins NCI’s OSTR Subsidy Program
National Cancer Center’s Office of Science and Technology Resources (OSTR) Recognizes HMT
HMT hires Alexander Buko Ph.D. as Vice President
HMT hires Alexander Buko Ph.D. as Vice
President, Business and Product Development and releases a new C13 flux analysis service, F-SCOPE.
Japanese Patent Office Issues HMT Patent
Japanese Patent Office Issues HMT, Inc., Patent for Method of Measuring Ethanolamine Phosphate
HMT Expands to U.S.
Proximity to world‐class institutions and pharmaceutical companies for cancer and biomarker research makes Cambridge the top choice for HMT.